ASPH and cholangiocarcinoma: ASPH has been previously shown to be upregulated in human CCA tumors by immunohistochemistry (IHC) using a monoclonal antibody (FB50); and more importantly, enhanced levels of ASPH were correlated with reduced survival rates as well as intrahepatic and lymph node metastases [13, 28].